8-K current report · filed Jul 1, 2026

SELECT MEDICAL HOLDINGS CORP (SEM) 8-K Current Report: July 1, 2026

Item 2.01Item 2.03Item 3.03Item 5.02Item 5.03Item 7.01Item EX-99.1Item 5.01Item 3.01Item 1.01SEM overview

Short answer

SELECT MEDICAL HOLDINGS CORP (SEM) filed an 8-K current report with the SEC on July 1, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 5.01 (Changes in Control of Registrant), Item 3.01 (Notice of Delisting), Item 1.01 (Entry into a Material Definitive Agreement). $1.0 billion incremental term loan added under Select Medical’s existing credit agreement.

  • This filing includes Item 3.01, an item that often signal trouble.

Why these 8-K items matter →

SELECT MEDICAL HOLDINGS CORP 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $1.0 billion incremental term loan added under Select Medical’s existing credit agreement
  • New borrowing increases leverage and future interest obligations
  • Amendment No. 12 modifies additional credit agreement provisions, potentially affecting covenant flexibility
  • Full terms, including pricing, maturity and use of proceeds, are in Exhibit 10.1

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Acquisition completed, with SEM common shares converted into cash consideration
  • Cash merger price: $16.50 per share, excluding rollover, restricted, excluded and properly appraised shares
  • Company restricted shares vested immediately before closing, then converted into $16.50 cash less tax withholdings
  • Rollover shares contributed to Parent and cancelled without consideration, reducing shares receiving merger proceeds

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 links financial-obligation details to the Item 1.01 material agreement disclosure
  • Investor impact depends on the borrowing amount, terms, maturity and purpose described under Item 1.01

Item 3.01 · Notice of Delisting

  • Merger completed June 30, 2026, triggering NYSE trading suspension before July 1
  • NYSE Form 25 requested to remove Select Medical shares from NYSE listing
  • Delisting will deregister shares under Exchange Act Section 12(b)
  • Form 15 planned, suspending SEC periodic reporting obligations for the shares

Item 3.03 · Material Modification to Rights of Security Holders

  • Merger completion eliminated existing SEM shares, with holders receiving merger consideration described under Item 2.01
  • Former shareholders ceased voting and ownership rights in Select Medical, subject only to merger-agreement or legal provisions
  • Event materially changes shareholder rights through conversion of equity into merger consideration at the merger effective time

Item 5.01 · Changes in Control of Registrant

  • Merger completed, triggering a change in control of Select Medical Holdings
  • Select Medical became wholly owned by Parent and certain rollover holders retaining restricted shares
  • Aggregate purchase price approximately $1.7 billion for outstanding company shares
  • Transaction funded through Welsh Carson equity, rollover contributions and third-party debt financing

Item 5.02 · Departure/Election of Directors or Officers

  • Merger completion removed seven directors, including William H. Frist and Daniel J. Thomas
  • Departures tied to merger closing, not disagreements with the company
  • Russell L. Carson, David S. Chernow and Robert A. Ortenzio now serve as directors
  • Board reduced from seven departing directors to three named directors, signaling post-merger governance reset

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

  • Certificate of incorporation replaced at merger closing under the Merger Agreement
  • Amended and restated bylaws adopted concurrently at the merger Effective Time
  • Governance documents now reflect post-merger corporate structure
  • Investor impact depends on Exhibit 3.1 and 3.2 provisions affecting shareholder rights and corporate governance

Item 7.01 · Regulation FD Disclosure

  • Press release announces completion of the Merger on June 30, 2026
  • Merger completion marks the transaction’s closing, potentially changing ownership, operations, and financial reporting
  • Exhibit 99.1 contains the substantive transaction details for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Acquisition completed by consortium led by Robert Ortenzio, Martin Jackson, and WCAS, effective July 1, 2026
  • Purchase price $16.50 per share, valuing Select Medical at approximately $3.9 billion
  • Consideration represented premiums of approximately 18% and 25% to unaffected and 90-day VWAP prices
  • Common stock ceasing trading; Select Medical delisting from NYSE on July 1, 2026
  • Existing officers continuing, while consortium assumes operational control and majority economic interest

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other SELECT MEDICAL HOLDINGS CORP 8-K filings

Get the next SEM 8-K as it lands

Follow SEM for push alerts, or ask the research agent what this filing means.